Smith & Nephew (SNN) Stock: Buy, Sell, or Hold?
SNN - Smith & Nephew plc
$30.96
0.07 (0.24%)
▲
5d:
+6.52%
30d:
+16.02%
90d:
-0.53%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When SNN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SNN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SNN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$48.00
Based on 6.2% avg growth
INTRINSIC VALUE TODAY
$29.81
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNN is currently trading at $30.95, which is considered extended relative to its 30-day fair value range of $26.67 to $28.99. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.8) compared to its historical average (14.8). Remarkably, the market is currently pricing in an annual earnings decline of 4.7% over the next few years. This pessimistic expectation contrasts with the company's recent 5.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SNN is in a downtrend. The price is approaching resistance at $31.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNN is in a downtrend. The price is approaching resistance at $31.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$26.67 -
$28.99
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
19.0%
All Signals
- BEARISH: Price extended above range (+6.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($32.32)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$26.67 -
$28.99
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$27.23
Resistance Level
$31.21
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.82
Wall Street Target
$32.32
(+4.7%)
Revenue Growth (YoY)
4.6%
Earnings Growth (YoY)
5.7%
Profit Margin
10.1%
Valuation Discount vs History
-4.7% cheaper
PE vs Historical
12.8 vs 14.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.7%
(market-implied from PE analysis)
1-Year Target
$29.43
(-5%)
2-Year Target
$28.05
(-9%)
3-Year Target
$26.73
(-13%)
3-Yr Target (if PE normalizes)
(PE: 13→15)
$30.84
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 8.3%)
$60.70
(+97%)
Base:
(SPY PE: 12.8, Growth: 8.3%)
$39.20
(+27%)
Bear:
(PE: 10.9, Growth: 8.3%)
$33.32
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 19.88 | Current EPS (TTM): $1.47
Bull Case
$52.67
(+71%)
Analyst growth 63.8%, PE expands to 21.9
Base Case
$47.88
(+55%)
Market implied 63.8%, PE stable at 19.9
Bear Case
$19.88
(-36%)
Severe decline -20.0%, PE contracts to 16.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.8 to 14.8
Stabilization Target:
$35.64
(+15.4%)
PE Expansion Potential:
+15.4%
Share & Embed Analysis
Last updated: October 23, 2026 2:42 PM ET
Data refreshes hourly during market hours. Next update: 3:42 PM
Data refreshes hourly during market hours. Next update: 3:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 41 HOLD |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 38 SELL |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 70 BUY |
|
PODD
Insulet Corporation |
BUY
26 analysts |
$167 | 37 SELL |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 44 HOLD |
